Metastatic breast cancer: Sequencing hormonal therapy and positioning of fulvestrant

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 2, 2006, Pages 524-526

  Vergote, I ^a,b   Amant, F ^a   Leunen, K ^a   Van Gorp, T ^a   Berteloot, P ^a   Neven, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GOSERELIN; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTHROPATHY; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DOWN REGULATION; DRUG BINDING; DRUG EFFICACY; DRUG TOLERABILITY; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 33748771449     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00687.x     Document Type: Conference Paper

References (11)

1. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
2. Howel A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospective planned combined survival analysis of two multicenter trials. Cancer 2005;104:236-9.
3. Vergote I, Robertson JFR. Fulvestrant is an effective and welltolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br J Cancer 2004;90(Suppl. 1):S11-4.
4. Howel A, Robertson JFR, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multination, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13.
5. Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 2006;17:200-4.
6. Perey L, Thürlimann B, Hawle H et al. Fulvestrant ('faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors [abstract]. Breast Cancer Res Treat 2004;88(Suppl. 1):S236. Abstract 6048.
7. Ingle JN, Rowland KM, Suman VJ et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group [abstract]. Breast Cancer Res Treat 2004;88(Suppl. 1):S38. Abstract 409.
8. Steger GG, Gips M, Simon SD et al. Fulvestrant ('Faslodex'): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 2005;31:S10-6.
9. Robertson JFR, Howell A, Gorbunova VA, Watanabe T, Pienkowski T, Lichinitser MR. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92:169-74.
10. Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK, Mauriac L. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79:207-11.
11. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(Suppl. 1):S15-8.